Edition:
United States

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

45.17USD
22 Sep 2017
Change (% chg)

-- (--)
Prev Close
$45.17
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
641,870
52-wk High
$63.73
52-wk Low
$26.26

Latest Key Developments (Source: Significant Developments)

UnitedHealth spokesman confirms plan to cover Sarepta's Exondys 51
Friday, 7 Oct 2016 02:28pm EDT 

UnitedHealth Group Inc : UnitedHealth spokesman confirms plans to cover Sarepta Therapeutics Inc's muscular dystrophy drug Exondys 51. (Reporting by Caroline Humer) ((caroline.humer@thomsonreuters.com;)).  Full Article

Summit's agreement with Sarepta also contains a standstill provision
Tuesday, 4 Oct 2016 07:05am EDT 

Summit Therapeutics Plc : Collaboration agreement with Sarepta also contains a standstill provision - SEC filing .Summit Therapeutics - Believes cash, cash equivalents, certain upfront payments from Sarepta collaboration to be sufficient to fund expenses through 2018.  Full Article

Sarepta and Summit enter into agreement for European rights to utrophin modulator pipeline
Tuesday, 4 Oct 2016 07:00am EDT 

Summit Therapeutics Plc : Summit receives $40 million upfront, with potential future ezutromid-related milestone payments totalling up to $522 million plus royalties . Sarepta also receives option for Latin American rights . As part of agreement, Sarepta also obtains an option to license latin american rights to Summit's utrophin modulator pipeline . If Sarepta elects to exercise option for Latin American rights, co would be entitled to additional fees, milestones and royalties . Sarepta and Summit to share research and development costs . Sarepta also receives option for Latin American rights . Sarepta Therapeutics and summit enter into exclusive license and collaboration agreement for european rights to summit’s utrophin modulator pipeline for the treatment of duchenne muscular dystrophy .Sarepta, co will share specified utrophin modulator-related research and development costs at a 45/55 pct split, respectively.  Full Article

Catabasis Pharma & Sarepta Therapeutics to collaborate in Duchenne muscular dystrophy
Thursday, 29 Sep 2016 08:00am EDT 

Catabasis Pharmaceuticals Inc : Collaboration to study exon skipping treatment by Sarepta with co's oral NF-KB inhibition treatment in mouse model of DMD . Catabasis Pharmaceuticals and Sarepta Therapeutics announce a joint research collaboration in Duchenne muscular dystrophy .Collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy.  Full Article

Sarepta Therapeutics reports pricing of $300 million public offering of common stock
Thursday, 22 Sep 2016 06:00pm EDT 

Sarepta Therapeutics Inc : Sarepta Therapeutics announces pricing of $300 million public offering of common stock . Says public offering priced at $59.75 per share . Priced public offering of an aggregate of 5.02 million shares of its common stock at a price to public of $59.75/share. .Sarepta Therapeutics announces pricing of $300 million public offering of common stock.  Full Article

Sarepta Therapeutics Q2 non-GAAP loss per share $1.19 excluding items
Tuesday, 19 Jul 2016 04:00pm EDT 

Sarepta Therapeutics Inc : No revenue was recognized for three months ended June 30, 2016 and 2015 . Sarepta Therapeutics announces second quarter 2016 financial results and recent corporate developments . Q2 non-GAAP loss per share $1.19 excluding items . Q2 loss per share $1.35 . Q2 earnings per share view $-1.19 -- Thomson Reuters I/B/E/S .Had $134.7 million in cash, cash equivalents, short-term investments and restricted cash as of June 30, 2016.  Full Article

Sarepta Therapeutics - FDA will not complete review of Eteplirsen NDA by PDUFA date
Wednesday, 25 May 2016 07:00am EDT 

Sarepta Therapeutics Inc : Sarepta Therapeutics announces FDA will not complete the review of the Eteplirsen new drug application by the PDUFA date . FDA has communicated that they will continue to work past pdufa goal date and strive to complete their work in as timely a manner as possible . FDA notified co that they are continuing review and internal discussions related to our pending NDA for Eteplirsen . fda notified co that it will not be able to complete work by Prescription Drug User Fee Act (PDUFA) goal date of May 26, 2016 . Sarepta Therapeutics announces FDA will not complete the review of the Eteplirsen new drug application by the PDUFA date .Sarepta Therapeutics announces FDA will not complete the review of the Eteplirsen new drug application by the PDUFA date.  Full Article

Sabby Healthcare Master Fund reports 5.15 pct passive stake in Sarepta Therapeutics - SEC filing
Friday, 6 May 2016 02:31pm EDT 

Sarepta Therapeutics Inc :Sabby Healthcare Master Fund, Ltd reports 5.15 percent passive stake in Sarepta Therapeutics Inc as of May 3, 2016 - SEC filing.  Full Article

Sarepta Therapeutics Inc says yet to receive new date for panel review of muscle wasting drug - Reuters News
Tuesday, 8 Mar 2016 06:43pm EST 

Sarepta Therapeutics Inc:Sarepta Therapeutics Inc said it had not received a rescheduled date for the review of its drug for a rare muscle wasting disorder by an FDA advisory panel and would slash about 17 percent of its workforce.The U.S. Food and Drug Administration on Jan. 20 postponed a meeting of the expert panel to review the company's drug, eteplirsen, due to inclement weather forecast for Washington DC.However, the company said on Tuesday it expected the meeting to be held before the May 26 deadline for review by the drug regulator.FDA staff said in January they were unconvinced about the effectiveness of the drug, which is designed to treat a subset of patients with Duchenne muscular dystrophy (DMD).The company said on Tuesday it would close down its Corvallis, Oregon facility and relocate some research activity and employees to its facilities in Andover and Cambridge, Massachusetts.  Full Article

Sarepta Therapeutics Announces Publication of Positive Long-Term Safety and Efficacy Data for Eteplirsen in the Annals of Neurology
Tuesday, 17 Nov 2015 08:43am EST 

Sarepta Therapeutics Inc :Announces publication of positive long-term safety and efficacy data for eteplirsen in the annals of neurology.Says study found that at three years of treatment, patients experienced a slower rate of disease progression.At 36 months, eteplirsen-treated patients showed statistically significant difference of 151 meters in six minute walk test.Eteplirsen-treated patients experienced lower incidence of loss of ambulation compared to natural history control patients.Says the investigational drug continued to be well-tolerated in study.  Full Article

Sarepta's shares jump on new DMD drug's promising trial results

Sarepta Therapeutics Inc's shares surged on Wednesday after the results of a trial on its drug to treat a fatal muscle-wasting disease showed it had the potential to be more effective than the company's approved drug for the same disease.